Iomab B is a monoclonal antibody conjugated commercialized by Actinium Pharmaceuticals, with a leading Phase III program in Relapsed Acute Myeloid Leukemia. According to Globaldata, it is involved in 13 clinical trials, of which 8 were completed, 2 are ongoing, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Iomab B’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Iomab B is expected to reach an annual total of $65 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Iomab B Overview

Iomab-B, a radioimmunoconjugate (BC8-I-131 construct) is under development for the treatment of relapsed and refractory follicular lymphoma, chronic lymphocytic leukemia, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, relapsed and refractory B-cell acute lymphoblastic leukemia and chronic myeloid leukemia (CML), acute myelocytic leukemia (AML), HIV-related lymphoma, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative disorders, relapsed and/or refractory elderly acute myeloid leukemia,chronic myelomonocytic leukaemia, refractory anemia with excess blasts, cytopenia, multiple myeloma and refractory anemia with ringed sideroblasts and for prevention of lymphodepletion during CAR-T therapy. The drug candidate is also under development for bone marrow conditioning before a hematopoietic stem cell transplant (HSCT), in relapsed/refractory elderly AML patients. It is administered intravenously. Iomab-B consists of the monoclonal antibody apamistamab and the beta emitting radioisotope I131 (I-131). It acts by targeting CD45 and is developed by using Alpha Particle Immunotherapy (APIT) platform. It was also under development for Hodgkin lymphoma, relapsed/refractory B-non-Hodgkin lymphoma (B-NHL), T-non-Hodgkin lymphoma(T-NHL) and mantle cell lymphoma, 

Actinium Pharmaceuticals Overview

Actinium Pharmaceuticals (Actinium) develops antibody radiation conjugates (ARC), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company’s pipeline products include Iomab-B for hematopoietic stem cell transplantation, Iomab-ACT for the treatment of GeneTx and Cell therapy conditioning, Actimab-A(CD33) for the treatment of relapsed/refractory AML. The three variants of Actimab-A developed by company are- Actimab-A (CD33) and CLAG-M; Actimab-A (CD33) and Venetoclax and Actimab-A (CD33) and Venetoclax with HMA. The company also offers AWE Technology Platform. It develops products to treat colon, prostrate and brain cancer. ATNM is headquartered in New York City, New York, the US.

The company reported revenues of (US Dollars) US$1.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$25 million in FY2021, compared to an operating loss of US$22.4 million in FY2020. The net loss of the company was US$24.8 million in FY2021, compared to a net loss of US$22.2 million in FY2020.

For a complete picture of Iomab B’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.